Sangamo Therapeutics shares are surging in Thursday's after-hours session after the company announced a new agreement with pharmaceutical giant Eli Lilly And Co.

Sangamo Therapeutics, Inc.’s SGMO share price has surged by 10.12%, which has investors questioning if this is right time to sell.

Sangamo Therapeutics, Inc.’s SGMO share price has dipped by 5.89%, which has investors questioning if this is right time to ...

Sangamo Therapeutics’ stock has plummeted by 50% in premarket trading after Pfizer ended the companies’ partnership to co-develop a gene therapy for haemophilia A. Sangamo announced it will ...

Now Gilead is spending a further $150 million upfront to access the cutting edge gene-editing technology of another Californian biotech, Sangamo. The ambition for this cancer-focused collaboration ...

RICHMOND, Calif., April 03, 2025--SANGAMO THERAPEUTICS ANNOUNCES CAPSID LICENSE AGREEMENT WITH LILLY TO DELIVER GENOMIC MEDICINES FOR DISEASES OF THE CENTRAL NERVOUS SYSTEM RICHMOND, Calif., ...

Sangamo said in November 2024 that the company only had enough money in the bank to last until the first quarter of 2025. It's not immediately clear how far Lilly’s $18 million cash payment will ...

Agreement grants Lilly rights to employ Sangamo’s novel proprietary capsid, STAC-BBB, for up to five potential disease targets Sangamo to receive an $18 million upfront license fee and is ...

Shares jump 59%, to $1.28, in post-market trading. Sangamo Therapeutics entered a licensing agreement with Eli Lilly. Under the deal, the genomic-medicine company Sangamo said Lilly would receive ...

The latest analyst rating for Sangamo Therapeutics (NASDAQ:SGMO) was provided by HC Wainwright & Co., and Sangamo Therapeutics reiterated their buy rating. The last upgrade for Sangamo ...

Genomic medicine company Sangamo Therapeutics said it entered a license agreement with Eli Lilly, under which Lilly received rights to employ Sangamo's proprietary capsid, STAC-BBB, for up to five ...

Sangamo to receive an $18 million upfront license fee and is eligible to earn up to $1.4 billion in additional licensed target fees and milestone payments across all five potential disease targets ...